Related Experiment Video
Updated: Jul 7, 2026
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy
Julia D Wulfkuhle1, Runa Speer, Mariaelena Pierobon
1Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110, USA. jwulfkuh@gmu.edu
Abstract:
Phosphoprotein driven cellular signaling events represent most of the new molecular targets for cancer treatment. Application of reverse-phase protein microarray technology for the study of ongoing signaling activity within breast tumor specimens holds great potential for elucidating and profiling signaling activity in real-time for patient-tailored therapy. Analysis of laser capture microdissection primary human breast tumors and metastatic lesions reveals pathway specific profiles and a new way to classify cancer based on functional signaling portraits. Moreover, the data demonstrate the requirement of laser capture microdissection for analysis and reveal the metastasis-specific changes that occur within a new microenvironment. Analysis of biopsy material from clinical trials for targeted therapeutics demonstrates the feasibility and utility of comprehensive signal pathway activation profiling for molecular analysis.
Insights
Reverse-phase protein microarray technology reveals functional signaling portraits in breast tumors. This approach enables real-time profiling for personalized cancer therapy and classification based on signaling activity.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Phosphoprotein signaling pathways are crucial molecular targets for cancer therapeutics.
- Reverse-phase protein microarrays (RPPA) offer a method for studying cellular signaling.
- Understanding signaling in breast tumors is key for developing targeted therapies.
Purpose of the Study:
- To profile real-time signaling activity in breast tumor specimens using RPPA.
- To explore pathway-specific signaling profiles in primary and metastatic breast cancer.
- To establish a novel cancer classification system based on functional signaling portraits.
Main Methods:
- Utilized reverse-phase protein microarray (RPPA) technology.
- Analyzed laser capture microdissection (LCM) of primary human breast tumors and metastatic lesions.
- Examined biopsy materials from clinical trials involving targeted therapeutics.
Main Results:
- Identified pathway-specific signaling profiles in breast cancer.
- Demonstrated the necessity of LCM for accurate signaling analysis.
- Revealed metastasis-specific signaling alterations in new microenvironments.
- Confirmed the feasibility of comprehensive signal pathway profiling for molecular analysis in clinical trials.
Conclusions:
- RPPA technology, combined with LCM, provides real-time functional signaling portraits of breast tumors.
- This approach facilitates a new method for classifying cancer based on signaling activity.
- The findings support the utility of signal pathway profiling for molecular analysis in targeted cancer therapy trials.
